HIV pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges
Date
2021-08
Authors
Coogan, Kristen
Assoumou, Sabrina A., MD MPH
Paniagua, Samantha M., MPH
Gonzalez, Priscilla, BS
Wang, Jianing, MSc
Beckwith, Curt G., MD
White, Laura, PhD
Taylor, Jessica L., MD
Samet, Jeffrey H., MD MA MPH
Linas, Benjamin P., MD MPH
Version
Accepted manuscript
OA Version
Citation
K. Coogan, S.A. Assoumou, MD MPH, S.M. Paniagua, MPH, P. Gonzalez, BS, J. Wang, MSc, C.G. Beckwith, MD, L. White, PhD, J.L. Taylor, MD, J.H. Samet, MD MA MPH, B.P. Linas, MD MPH. 2021. "HIV Pre-Exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center during the Opioid Epidemic: Opportunities and Challenges" AIDS and Behavior, Volume 25, Issue 8, pp.2591-2598. https://doi.org/10.1007/s10461-021-03220-0
Abstract
Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) and buprenorphine decrease HIV acquisition. Between November, 2016 - July, 2017, we surveyed persons (N=200) at a drug detoxification center to assess their interest in PrEP and in buprenorphine, and to examine factors associated with such interests. Participants had a mean [SD] age of 39 [10] years. Over the previous 6 months, 58% (117/200) injected drugs and 50% (85/171) had condomless sex. Only 22% (26/117) of persons who injected drugs were aware of PrEP, yet 74% (86/116) and 72% (84/116) were interested in oral or injectable PrEP, respectively. Thirty-eight percent (47/125) of persons not receiving buprenorphine or methadone expressed interest in buprenorphine. After multivariable adjustment, Latinx ethnicity was associated with interest in PrEP (aOR: 3.80; 95% CI, 1.37-10.53), while male gender (aOR: 2.76; 95% CI, 1.21-6.34) was associated with interest in buprenorphine. Opportunities exist to implement PrEP and buprenorphine within drug detoxification centers.